Is MediWound Ltd. overvalued or undervalued?

As of 6 August 2020, MediWound Ltd. has moved from a very attractive to a risky valuation grade, indicating a significant shift in its financial outlook. The company is currently considered overvalued, especially given its negative earnings and substantial losses reflected in its ratios. The P/E ratio is not applicable due to the company being loss-making, while the Price to Book Value stands at 7.46, and the EV to EBITDA is at -10.10, further highlighting the company's challenges.
In comparison to its peers, MediWound's EV to EBIT ratio of -10.0738 is notably worse than Eton Pharmaceuticals, which has an EV to EBITDA of 377.6356, and Ocugen, with an EV to EBITDA of -5.6869. These comparisons underscore the financial difficulties faced by MediWound. Additionally, the company's recent stock performance shows a decline of 7.32% over the past week, contrasting with the S&P 500's minimal drop of 0.13%, which reinforces the notion of overvaluation amidst its current financial instability.